PDCO Price Prediction Next Week
Analysis and Insights
News and Sentiment Analysis:
Patterson Companies (PDCO) has recently experienced mixed sentiment following its Q3 earnings report, which missed both EPS and revenue expectations. Despite this, the stock has shown resilience, likely due to the market pricing in the likelihood of a higher bid following the expiration of the go-shop period. Analysts from Evercore ISI and Morgan Stanley have maintained a Hold rating with price targets of $31.40 and $31.35, respectively.
Technical Indicators:
- RSI (14-period): 74.18, indicating overbought conditions.
- MACD: Showing a slight bullish signal with a positive divergence.
- Bollinger Bands: The stock is trading near the upper band, suggesting potential volatility.
- Fibonacci Levels: Resistance at $31.18 and $31.21; support at $31.07 and $30.99.
Price Prediction and Recommendation:
Given the overbought RSI and tight Bollinger Bands, PDCO may experience a slight pullback. The stock is likely to test the lower Fibonacci support levels. Based on current analysis, the stock is expected to trade around $30.80 next week. Considering the technical indicators and analyst consensus, it may be prudent to sell or hold off on buying at current levels.
PDCO Similar Chart Price Prediction
The price of PDCO is predicted to go up 7.98%, based on the high correlation periods with GTY. The similarity of these two price pattern on the periods is 98.38%.
PDCO
GTY
Up: 7.98%Similarity: 98.38%
PDCO Revenue Forecast
PDCO EPS Forecast
PDCO FAQs
What is PDCO revenue forecast for next quarter？
What is PDCO eps forecast for next quarter？
PDCO Analyst's Forecast
Erin Wright
Morgan Stanley
Hold
2024-12-17
Price Target
$27 → $31
Upside
+1.46%
Morgan Stanley raised the firm's price target on Patterson Companies to $31.35 from $27 and keeps an Equal Weight rating on the shares. The dental industry "continues to be plagued by prolonged turnaround stories," which the firm believes will serve as an impetus for more private equity interest, with the latest being Patient Square Capital's acquisition of Patterson, the analyst tells investors. The firm's revised target reflects the takeout price agreed upon by Patient Square.
Jeff Johnson
Baird
Hold
2024-12-12
Price Target
$25 → $31
Downside
-0.26%
Michael Cherny
Leerink Partners
Buy → Hold
2024-12-11
Price Target
$29 → $31
Upside
+0.87%
